Skip to content

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02247531
Acronym
SPECTRI
Enrollment
975
Registered
2014-09-25
Start date
2014-10-06
Completion date
2018-01-23
Last updated
2019-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geographic Atrophy

Brief summary

This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Interventions

10 mg dose of lampalizumab administered intravitreally.

OTHERSham Comparator

A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.

Sponsors

Hoffmann-La Roche
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participants aged greater than or equal to (\>/=) 50 years * Well demarcated area(s) of Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) with no evidence of prior or active choroidal neovascularization (CNV) in both eyes

Exclusion criteria

Ocular

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Geographic Atropy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 48Baseline, Week 48The change in GA lesion area was measured by FAF and analysis of FAF images was performed by the central reading center. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression).
Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48Baseline, Week 48For CFI profile, positive or negative biomarker status refers to the presence (carrier) or absence of the risk allele at CFI and at least one risk allele at complement factor H (CFH) or risk locus containing both complement component 2 and complement factor B (C2/CFB).The change in GA lesion area was measured by FAF and analysis of FAF images was performed by the central reading center. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression).

Secondary

MeasureTime frameDescription
Change From Baseline in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Week 48Baseline, Week 48BCVA score was based on the number of letters read correctly on the ETDRS visual acuity chart assessed at a starting distance of 4 meters (m). A decrease in the VA score indicates a worsening in visual acuity. BCVA score testing was performed prior to dilating the eyes. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. BCVA score ranges from 0 to 100 letters in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A negative change from baseline indicates a decrease in the visual acuity; disease worsening.
Percentage of Participants With Less Than 15 Letters Loss From Baseline in BCVA Score at Week 48Week 48Loss of less than 15 letters from baseline was assessed by the ETDRS chart at a starting distance of 4 meters (m). Data were collected up to Week 48 instead of Week 96, due to early termination of the study.
Change From Baseline in Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions at Week 48Baseline, Week 48The low luminance visual acuity was measured by placing a 2.0-log-unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart. The assessment was performed prior to dilating the eyes. A negative change from baseline indicates a decrease in the visual acuity; disease worsening. Data were collected up to Week 48 instead of Week 96, due to early termination of the study.
Percentage of Participants With Less Than 15 Letters Loss From Baseline in LLVA Score at Week 48Week 48Loss of less than 15 letters from baseline was assessed by the ETDRS chart at a starting distance of 4 m. Data were collected up to Week 48 instead of Week 96, due to early termination of the study.
Change From Baseline in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Charts or Radner Reading Charts at Week 48Baseline, Week 48MNRead acuity cards were continuous-text reading-acuity cards suitable for measuring the reading acuity and reading speed of normal and low-vision participants. The MNRead acuity cards consisted of single, simple sentences with equal numbers of characters. A stopwatch was used to record time to a tenth of a second. Sentences that could not be read or were not attempted due to vision should be recorded as 0 for time and 10 for errors. The Radner Reading Cards were suitable for measuring reading speed, reading visual acuity, and critical print size. The reading test was stopped when the reading time was longer than 20 seconds or when the participant was making severe errors. A negative change from baseline indicates a decrease in the binocular reading speed; disease worsening. Data were collected up to Week 48 instead of Week 96, due to early termination of the study.
Change From Baseline in Number of Absolute Scotomatous Points Assessed by Mesopic Microperimetry at Week 48Baseline, Week 48Scotomatous points were the testing points on microperimetry examination that were centered on the macula and reported a lack of retinal sensitivity within the range tested. Mesopic microperimetry assessments were performed post-dilation on the study eye only, and the data was forwarded to the central reading center. A positive change from baseline indicates an increase in the number of absolute scotomatous points (more lack of retinal sensitivity); disease worsening. Data were collected up to Week 48 instead of Week 96, due to early termination of the study.
Change From Baseline in NEI VFQ-25 Distance Activity Subscale Score at Week 48Baseline, Week 48NEI-VFQ-25 questionnaire included 25 items based on which distance activities were measured. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs. Response to each question converted to 0-100 score. Subscale=average of items contributing to score. For this subscale the score range is 0 to 100, a higher score represents better functioning. A negative change from baseline indicates a decrease in the distance visual activities; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Change From Baseline in National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score at Week 48Baseline, Week 48NEI-VFQ-25 questionnaire included 25 items based on which overall composite VFQ score and 12 subscales were derived: near activities, distance activities, general health, general vision, ocular pain, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision and peripheral vision. Response to each question converted to 0-100 score. Each subscale or total score is the average of items contributing to the score. For each subscale and total score the score range is 0 to 100 with a higher score representing better functioning. A negative change from baseline indicates a decrease in the visual functioning; disease worsening. Data were collected up to Week 48 instead of Week 96, due to early termination of the study.
Change From Baseline in NEI VFQ-25 Near Activity Subscale Score at Week 48Baseline, Week 48NEI-VFQ-25 questionnaire included 25 items based on which near activities were measured. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf. Response to each question converted to 0-100 score. Subscale=average of items contributing to score. For this subscale the score range is 0 to 100, a higher score represents better functioning. A negative change from baseline indicates a decrease in the near visual activities; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Change From Baseline in Mean Functional Reading Independence (FRI) Index at Week 48Baseline, Week 48The FRI was an interviewer-administered questionnaire with 7 items on functional reading activities most relevant to GA AMD participants. It has one total index score. For each FRI Index reading activity performed in the past 7 days, participants were asked about the extent to which they required vision aids, adjustments in the activity, or help from another participant. Mean FRI Index scores range from 1 to 4, with higher scores indicating greater independence. A negative change from baseline indicates a decrease in the FRI; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Change From Baseline in Monocular Maximum Reading Speed as Assessed by MNRead Charts or Radner Reading Charts at Week 48Baseline, Week 48MNRead acuity cards were continuous-text reading-acuity cards suitable for measuring reading acuity and reading speed of normal and low-vision participants. A stopwatch was used to record time to a tenth of a second. Sentences that could not be read or were not attempted due to vision should be recorded as 0 for time and 10 for errors. Radner Reading Cards were suitable for measuring reading speed, reading visual acuity, and critical print size. Reading test was stopped when reading time was longer than 20 seconds or when participant was making severe errors. A negative change from baseline indicates a decrease in the monocular reading speed; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.
Change From Baseline in Macular Sensitivity as Assessed by Mesopic Microperimetry at Week 48Baseline, Week 48Mesopic microperimetry was used to assess macular sensitivity and assessments were performed post-dilation on the study eye only, and the data was forwarded to the central reading center. A negative change from baseline indicates a decrease in the mean macular sensitivity; disease worsening. Data were collected up to Week 48 instead of Week 96, due to early termination of the study.

Countries

Argentina, Australia, Austria, Belgium, Denmark, France, Germany, Hungary, Italy, Mexico, Netherlands, Peru, Poland, Portugal, Russia, Slovakia, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom, United States

Participant flow

Recruitment details

A total of 975 participants were randomized to the study at 144 study sites across 22 countries. The study was terminated early by the Sponsor due to lack of efficacy.

Pre-assignment details

This study enrolled participants with bilateral Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) and no signs of prior or active choroidal neovascularization (CNV), age \>= 50 years with a valid complement factor I (CFI)-profile biomarker result.

Participants by arm

ArmCount
Sham Comparator
Participants received sham comparator, once every 4 weeks (Q4W) starting at the Day 1 visit or once every 6 weeks (Q6W) starting at the Day 1 visit.
321
Lampalizumab Q4W
Participants received 10 mg (milligrams) dose of lampalizumab by intravitreal injection Q4W starting at the Day 1 visit.
330
Lampalizumab Q6W
Participants received 10 mg dose of lampalizumab by intravitreal injection Q6W starting at the Day 1 visit.
324
Total975

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyAdverse Event349
Overall StudyDeath895
Overall StudyLost to Follow-up183
Overall StudyNon-compliance220
Overall StudyPhysician Decision022
Overall StudyStudy Terminated by Sponsor646662
Overall StudyUnspecified Reason234
Overall StudyWithdrawal by Subject263125

Baseline characteristics

CharacteristicLampalizumab Q4WTotalLampalizumab Q6WSham Comparator
Age, Continuous77.3 years
STANDARD_DEVIATION 7.8
77.9 years
STANDARD_DEVIATION 8.1
78.7 years
STANDARD_DEVIATION 8
77.6 years
STANDARD_DEVIATION 8.3
Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study66.0 letters
STANDARD_DEVIATION 9.6
66.0 letters
STANDARD_DEVIATION 9.7
65.7 letters
STANDARD_DEVIATION 9.8
66.1 letters
STANDARD_DEVIATION 9.8
Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test or Radner Reading Charts104.38 words per minute (wpm)
STANDARD_DEVIATION 54.35
103.09 words per minute (wpm)
STANDARD_DEVIATION 55.94
99.75 words per minute (wpm)
STANDARD_DEVIATION 56.56
105.16 words per minute (wpm)
STANDARD_DEVIATION 56.94
GA Area in CFI Negative Participants8.499 mm^2
STANDARD_DEVIATION 4.044
8.144 mm^2
STANDARD_DEVIATION 4.073
8.268 mm^2
STANDARD_DEVIATION 4.281
7.650 mm^2
STANDARD_DEVIATION 3.862
GA Area in Complement Factor I (CFI) Positive Participants8.183 mm^2
STANDARD_DEVIATION 3.835
8.109 mm^2
STANDARD_DEVIATION 4.074
8.652 mm^2
STANDARD_DEVIATION 4.25
7.491 mm^2
STANDARD_DEVIATION 4.068
Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluoresence (FAF)8.308 millimeter square (mm^2)
STANDARD_DEVIATION 3.916
8.123 millimeter square (mm^2)
STANDARD_DEVIATION 4.071
8.498 millimeter square (mm^2)
STANDARD_DEVIATION 4.26
7.554 millimeter square (mm^2)
STANDARD_DEVIATION 3.983
Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions36.1 letters
STANDARD_DEVIATION 17.5
36.2 letters
STANDARD_DEVIATION 16.9
35.8 letters
STANDARD_DEVIATION 16.8
36.8 letters
STANDARD_DEVIATION 16.5
Macular Sensitivity as Assessed by Mesopic Microperimetry5.7 decibel (dB)
STANDARD_DEVIATION 3.8
5.8 decibel (dB)
STANDARD_DEVIATION 3.5
5.3 decibel (dB)
STANDARD_DEVIATION 3.2
6.5 decibel (dB)
STANDARD_DEVIATION 3.3
Mean Functional Reading Independence (FRI) Index2.66 score on a scale
STANDARD_DEVIATION 0.82
2.67 score on a scale
STANDARD_DEVIATION 0.83
2.64 score on a scale
STANDARD_DEVIATION 0.87
2.70 score on a scale
STANDARD_DEVIATION 0.79
Monocular Maximum Reading Speed as Assessed by MNRead Charts or Radner Reading Charts80.38 wpm
STANDARD_DEVIATION 53.7
78.70 wpm
STANDARD_DEVIATION 53.85
74.52 wpm
STANDARD_DEVIATION 50.11
81.20 wpm
STANDARD_DEVIATION 57.48
National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score62.88 score on a scale
STANDARD_DEVIATION 17.5
63.90 score on a scale
STANDARD_DEVIATION 17.02
64.03 score on a scale
STANDARD_DEVIATION 17.65
64.84 score on a scale
STANDARD_DEVIATION 15.8
NEI VFQ-25 Distance Activity Subscale Score58.57 scores on a scale
STANDARD_DEVIATION 22.03
60.70 scores on a scale
STANDARD_DEVIATION 21.71
60.95 scores on a scale
STANDARD_DEVIATION 21.55
62.68 scores on a scale
STANDARD_DEVIATION 21.41
NEI VFQ-25 Near Activity Subscale Score51.68 score on a scale
STANDARD_DEVIATION 21.92
52.92 score on a scale
STANDARD_DEVIATION 21.34
53.24 score on a scale
STANDARD_DEVIATION 22.07
53.89 score on a scale
STANDARD_DEVIATION 19.91
Number of Absolute Scotomatous Points as Assessed by Mesopic Micrometry28.2 number of absolute scotomatous points
STANDARD_DEVIATION 17.3
26.6 number of absolute scotomatous points
STANDARD_DEVIATION 15.3
27.9 number of absolute scotomatous points
STANDARD_DEVIATION 14.4
23.2 number of absolute scotomatous points
STANDARD_DEVIATION 13.5
Race/Ethnicity, Customized
American Indian or Alaska Native
3 Participants6 Participants1 Participants2 Participants
Race/Ethnicity, Customized
Asian
1 Participants5 Participants1 Participants3 Participants
Race/Ethnicity, Customized
Black or African American
1 Participants1 Participants0 Participants0 Participants
Race/Ethnicity, Customized
Hispanic or Latino
9 Participants37 Participants16 Participants12 Participants
Race/Ethnicity, Customized
Multiple
0 Participants3 Participants1 Participants2 Participants
Race/Ethnicity, Customized
Native Hawaiian or other Pacific Islander
0 Participants1 Participants0 Participants1 Participants
Race/Ethnicity, Customized
Not Hispanic or Latino
310 Participants905 Participants297 Participants298 Participants
Race/Ethnicity, Customized
Not Stated
8 Participants23 Participants8 Participants7 Participants
Race/Ethnicity, Customized
Unknown
3 Participants10 Participants3 Participants4 Participants
Race/Ethnicity, Customized
White
315 Participants936 Participants315 Participants306 Participants
Sex: Female, Male
Female
197 Participants578 Participants190 Participants191 Participants
Sex: Female, Male
Male
133 Participants397 Participants134 Participants130 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
9 / 31810 / 3297 / 323
other
Total, other adverse events
227 / 318268 / 329253 / 323
serious
Total, serious adverse events
99 / 318113 / 329111 / 323

Outcome results

Primary

Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48

For CFI profile, positive or negative biomarker status refers to the presence (carrier) or absence of the risk allele at CFI and at least one risk allele at complement factor H (CFH) or risk locus containing both complement component 2 and complement factor B (C2/CFB).The change in GA lesion area was measured by FAF and analysis of FAF images was performed by the central reading center. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression).

Time frame: Baseline, Week 48

Population: ITT population included all the participants who were randomized to the study. The analysis was done specifically for CFI-positive and negative participants.

ArmMeasureGroupValue (MEAN)Dispersion
Sham ComparatorChange From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48CFI-Positive Participants2.007 mm^2Standard Error 0.074
Sham ComparatorChange From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48CFI-Negative Participants1.809 mm^2Standard Error 0.087
Lampalizumab Q4WChange From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48CFI-Positive Participants2.057 mm^2Standard Error 0.072
Lampalizumab Q4WChange From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48CFI-Negative Participants2.149 mm^2Standard Error 0.087
Lampalizumab Q6WChange From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48CFI-Positive Participants2.032 mm^2Standard Error 0.073
Lampalizumab Q6WChange From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48CFI-Negative Participants1.991 mm^2Standard Error 0.085
Comparison: CFI Positive: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline GA area, lesion location, contiguity, biomarker status, modified baseline BCVA and sex.p-value: 0.633395% CI: [-0.153, 0.252]MMRM
Comparison: CFI Positive: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline GA area, lesion location, contiguity, biomarker status, modified baseline BCVA and sex.p-value: 0.810595% CI: [-0.18, 0.23]MMRM
Comparison: CFI Negative: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline GA area, lesion location, contiguity, biomarker status, modified baseline BCVA and sex.p-value: 0.006395% CI: [0.097, 0.584]MMRM
Comparison: CFI Negative: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline GA area, lesion location, contiguity, biomarker status, modified baseline BCVA and sex.p-value: 0.135995% CI: [-0.058, 0.422]MMRM
Primary

Change From Baseline in Geographic Atropy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 48

The change in GA lesion area was measured by FAF and analysis of FAF images was performed by the central reading center. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression).

Time frame: Baseline, Week 48

Population: Intent-to-treat (ITT) population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in Mixed-effect model repeated measures (MMRM analysis).

ArmMeasureValue (MEAN)Dispersion
Sham ComparatorChange From Baseline in Geographic Atropy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 481.932 millimeter square (mm^2)Standard Error 0.056
Lampalizumab Q4WChange From Baseline in Geographic Atropy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 482.089 millimeter square (mm^2)Standard Error 0.056
Lampalizumab Q6WChange From Baseline in Geographic Atropy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 482.019 millimeter square (mm^2)Standard Error 0.056
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline GA area, lesion location, contiguity, biomarker status, modified baseline BCVA and sex.p-value: 0.047995% CI: [0.001, 0.313]MMRM
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline GA area, lesion location, contiguity, biomarker status, modified baseline BCVA and sex.p-value: 0.273995% CI: [-0.069, 0.243]MMRM
Secondary

Change From Baseline in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Week 48

BCVA score was based on the number of letters read correctly on the ETDRS visual acuity chart assessed at a starting distance of 4 meters (m). A decrease in the VA score indicates a worsening in visual acuity. BCVA score testing was performed prior to dilating the eyes. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. BCVA score ranges from 0 to 100 letters in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A negative change from baseline indicates a decrease in the visual acuity; disease worsening.

Time frame: Baseline, Week 48

Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.

ArmMeasureValue (MEAN)Dispersion
Sham ComparatorChange From Baseline in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Week 48-5.3 lettersStandard Error 0.7
Lampalizumab Q4WChange From Baseline in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Week 48-4.6 lettersStandard Error 0.7
Lampalizumab Q6WChange From Baseline in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Week 48-5.1 lettersStandard Error 0.7
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline BCVA, GA lesion location, biomarker status, and sex.p-value: 0.465195% CI: [-1.2, 2.5]MMRM
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline BCVA, GA lesion location, biomarker status, and sex.p-value: 0.788595% CI: [-1.6, 2.1]MMRM
Secondary

Change From Baseline in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Charts or Radner Reading Charts at Week 48

MNRead acuity cards were continuous-text reading-acuity cards suitable for measuring the reading acuity and reading speed of normal and low-vision participants. The MNRead acuity cards consisted of single, simple sentences with equal numbers of characters. A stopwatch was used to record time to a tenth of a second. Sentences that could not be read or were not attempted due to vision should be recorded as 0 for time and 10 for errors. The Radner Reading Cards were suitable for measuring reading speed, reading visual acuity, and critical print size. The reading test was stopped when the reading time was longer than 20 seconds or when the participant was making severe errors. A negative change from baseline indicates a decrease in the binocular reading speed; disease worsening. Data were collected up to Week 48 instead of Week 96, due to early termination of the study.

Time frame: Baseline, Week 48

Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.

ArmMeasureValue (MEAN)Dispersion
Sham ComparatorChange From Baseline in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Charts or Radner Reading Charts at Week 48-15.27 words per minute (wpm)Standard Error 2.33
Lampalizumab Q4WChange From Baseline in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Charts or Radner Reading Charts at Week 48-13.92 words per minute (wpm)Standard Error 2.36
Lampalizumab Q6WChange From Baseline in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Charts or Radner Reading Charts at Week 48-14.20 words per minute (wpm)Standard Error 2.31
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, baseline maximum reading speed, type of reading charts, baseline BCVA of better seeing eye, biomarker status, and sex.p-value: 0.684195% CI: [-5.16, 7.85]MMRM
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, baseline maximum reading speed, type of reading charts, baseline BCVA of better seeing eye, biomarker status, and sex.p-value: 0.744395% CI: [-5.37, 7.52]MMRM
Secondary

Change From Baseline in Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions at Week 48

The low luminance visual acuity was measured by placing a 2.0-log-unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart. The assessment was performed prior to dilating the eyes. A negative change from baseline indicates a decrease in the visual acuity; disease worsening. Data were collected up to Week 48 instead of Week 96, due to early termination of the study.

Time frame: Baseline, Week 48

Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.

ArmMeasureValue (MEAN)Dispersion
Sham ComparatorChange From Baseline in Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions at Week 48-2.5 lettersStandard Error 0.6
Lampalizumab Q4WChange From Baseline in Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions at Week 48-2.6 lettersStandard Error 0.6
Lampalizumab Q6WChange From Baseline in Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions at Week 48-3.6 lettersStandard Error 0.6
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline LLVA, GA lesion location, biomarker status, modified baseline BCVA ETDRS chart Snellen equivalent category, and sex.p-value: 0.893195% CI: [-1.8, 1.5]MMRM
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline LLVA, GA lesion location, biomarker status, modified baseline BCVA ETDRS chart Snellen equivalent category, and sex.p-value: 0.175495% CI: [-2.8, 0.5]MMRM
Secondary

Change From Baseline in Macular Sensitivity as Assessed by Mesopic Microperimetry at Week 48

Mesopic microperimetry was used to assess macular sensitivity and assessments were performed post-dilation on the study eye only, and the data was forwarded to the central reading center. A negative change from baseline indicates a decrease in the mean macular sensitivity; disease worsening. Data were collected up to Week 48 instead of Week 96, due to early termination of the study.

Time frame: Baseline, Week 48

Population: The microperimetry analysis population consisted of all participants who met the microperimetry eligibility criteria assessed by the reading center (participants at selected sites only; participants grouped according to treatment assigned at randomization). Participants analyzed in this outcome measure were those included in MMRM analysis.

ArmMeasureValue (MEAN)Dispersion
Sham ComparatorChange From Baseline in Macular Sensitivity as Assessed by Mesopic Microperimetry at Week 48-0.99 decibel (dB)Standard Error 0.36
Lampalizumab Q4WChange From Baseline in Macular Sensitivity as Assessed by Mesopic Microperimetry at Week 48-0.89 decibel (dB)Standard Error 0.34
Lampalizumab Q6WChange From Baseline in Macular Sensitivity as Assessed by Mesopic Microperimetry at Week 48-1.25 decibel (dB)Standard Error 0.35
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline mean macular sensitivity, GA lesion location, contiguity, biomarker status, modified baseline BCVA and sex.p-value: 0.835895% CI: [-0.88, 1.09]MMRM
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline mean macular sensitivity, GA lesion location, contiguity, biomarker status, modified baseline BCVA and sex.p-value: 0.611795% CI: [-1.25, 0.74]MMRM
Secondary

Change From Baseline in Mean Functional Reading Independence (FRI) Index at Week 48

The FRI was an interviewer-administered questionnaire with 7 items on functional reading activities most relevant to GA AMD participants. It has one total index score. For each FRI Index reading activity performed in the past 7 days, participants were asked about the extent to which they required vision aids, adjustments in the activity, or help from another participant. Mean FRI Index scores range from 1 to 4, with higher scores indicating greater independence. A negative change from baseline indicates a decrease in the FRI; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

Time frame: Baseline, Week 48

Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.

ArmMeasureValue (MEAN)Dispersion
Sham ComparatorChange From Baseline in Mean Functional Reading Independence (FRI) Index at Week 48-0.16 score on a scaleStandard Error 0.04
Lampalizumab Q4WChange From Baseline in Mean Functional Reading Independence (FRI) Index at Week 48-0.12 score on a scaleStandard Error 0.04
Lampalizumab Q6WChange From Baseline in Mean Functional Reading Independence (FRI) Index at Week 48-0.14 score on a scaleStandard Error 0.04
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, baseline Mean FRI Index score, baseline BCVA of better seeing eye, biomarker status, and sex.p-value: 0.522795% CI: [-0.07, 0.14]MMRM
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, baseline Mean FRI Index score, baseline BCVA of better seeing eye, biomarker status, and sex.p-value: 0.747595% CI: [-0.09, 0.13]MMRM
Secondary

Change From Baseline in Monocular Maximum Reading Speed as Assessed by MNRead Charts or Radner Reading Charts at Week 48

MNRead acuity cards were continuous-text reading-acuity cards suitable for measuring reading acuity and reading speed of normal and low-vision participants. A stopwatch was used to record time to a tenth of a second. Sentences that could not be read or were not attempted due to vision should be recorded as 0 for time and 10 for errors. Radner Reading Cards were suitable for measuring reading speed, reading visual acuity, and critical print size. Reading test was stopped when reading time was longer than 20 seconds or when participant was making severe errors. A negative change from baseline indicates a decrease in the monocular reading speed; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

Time frame: Baseline, Week 48

Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.

ArmMeasureValue (MEAN)Dispersion
Sham ComparatorChange From Baseline in Monocular Maximum Reading Speed as Assessed by MNRead Charts or Radner Reading Charts at Week 48-16.58 wpmStandard Error 2.3
Lampalizumab Q4WChange From Baseline in Monocular Maximum Reading Speed as Assessed by MNRead Charts or Radner Reading Charts at Week 48-16.46 wpmStandard Error 2.3
Lampalizumab Q6WChange From Baseline in Monocular Maximum Reading Speed as Assessed by MNRead Charts or Radner Reading Charts at Week 48-18.30 wpmStandard Error 2.27
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, baseline maximum reading speed, biomarker status, modified baseline BCVA, and sex.p-value: 0.971395% CI: [-6.28, 6.52]MMRM
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, baseline maximum reading speed, biomarker status, modified baseline BCVA, and sex.p-value: 0.594595% CI: [-8.08, 4.63]MMRM
Secondary

Change From Baseline in National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score at Week 48

NEI-VFQ-25 questionnaire included 25 items based on which overall composite VFQ score and 12 subscales were derived: near activities, distance activities, general health, general vision, ocular pain, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision and peripheral vision. Response to each question converted to 0-100 score. Each subscale or total score is the average of items contributing to the score. For each subscale and total score the score range is 0 to 100 with a higher score representing better functioning. A negative change from baseline indicates a decrease in the visual functioning; disease worsening. Data were collected up to Week 48 instead of Week 96, due to early termination of the study.

Time frame: Baseline, Week 48

Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.

ArmMeasureValue (MEAN)Dispersion
Sham ComparatorChange From Baseline in National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score at Week 48-2.08 score on a scaleStandard Error 0.74
Lampalizumab Q4WChange From Baseline in National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score at Week 48-0.86 score on a scaleStandard Error 0.73
Lampalizumab Q6WChange From Baseline in National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score at Week 48-1.05 score on a scaleStandard Error 0.72
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, baseline score, baseline BCVA of better seeing eye, biomarker status, and sex.p-value: 0.243895% CI: [-0.83, 3.27]MMRM
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, baseline score, baseline BCVA of better seeing eye, biomarker status, and sex.p-value: 0.320295% CI: [-1.01, 3.07]MMRM
Secondary

Change From Baseline in NEI VFQ-25 Distance Activity Subscale Score at Week 48

NEI-VFQ-25 questionnaire included 25 items based on which distance activities were measured. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs. Response to each question converted to 0-100 score. Subscale=average of items contributing to score. For this subscale the score range is 0 to 100, a higher score represents better functioning. A negative change from baseline indicates a decrease in the distance visual activities; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

Time frame: Baseline, Week 48

Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.

ArmMeasureValue (MEAN)Dispersion
Sham ComparatorChange From Baseline in NEI VFQ-25 Distance Activity Subscale Score at Week 48-2.83 score on a scaleStandard Error 1.04
Lampalizumab Q4WChange From Baseline in NEI VFQ-25 Distance Activity Subscale Score at Week 48-1.80 score on a scaleStandard Error 1.03
Lampalizumab Q6WChange From Baseline in NEI VFQ-25 Distance Activity Subscale Score at Week 48-2.24 score on a scaleStandard Error 1.01
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, baseline score, baseline BCVA of better seeing eye, biomarker status, and sex.p-value: 0.479595% CI: [-1.84, 3.91]MMRM
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, baseline score, baseline BCVA of better seeing eye, biomarker status, and sex.p-value: 0.682295% CI: [-2.26, 3.45]MMRM
Secondary

Change From Baseline in NEI VFQ-25 Near Activity Subscale Score at Week 48

NEI-VFQ-25 questionnaire included 25 items based on which near activities were measured. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf. Response to each question converted to 0-100 score. Subscale=average of items contributing to score. For this subscale the score range is 0 to 100, a higher score represents better functioning. A negative change from baseline indicates a decrease in the near visual activities; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

Time frame: Baseline, Week 48

Population: ITT population included all the participants who were randomized to the study. Participants analyzed in this outcome measure were those included in MMRM analysis.

ArmMeasureValue (MEAN)Dispersion
Sham ComparatorChange From Baseline in NEI VFQ-25 Near Activity Subscale Score at Week 48-4.12 score on a scaleStandard Error 0.91
Lampalizumab Q4WChange From Baseline in NEI VFQ-25 Near Activity Subscale Score at Week 48-1.49 score on a scaleStandard Error 0.89
Lampalizumab Q6WChange From Baseline in NEI VFQ-25 Near Activity Subscale Score at Week 48-1.93 score on a scaleStandard Error 0.88
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, baseline score, baseline BCVA of better seeing eye, biomarker status, and sex.p-value: 0.038895% CI: [0.14, 5.14]MMRM
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, baseline score, baseline BCVA of better seeing eye, biomarker status, and sex.p-value: 0.083395% CI: [-0.29, 4.68]MMRM
Secondary

Change From Baseline in Number of Absolute Scotomatous Points Assessed by Mesopic Microperimetry at Week 48

Scotomatous points were the testing points on microperimetry examination that were centered on the macula and reported a lack of retinal sensitivity within the range tested. Mesopic microperimetry assessments were performed post-dilation on the study eye only, and the data was forwarded to the central reading center. A positive change from baseline indicates an increase in the number of absolute scotomatous points (more lack of retinal sensitivity); disease worsening. Data were collected up to Week 48 instead of Week 96, due to early termination of the study.

Time frame: Baseline, Week 48

Population: The microperimetry analysis population consisted of all participants who met the microperimetry eligibility criteria assessed by the reading center (participants at selected sites only; participants grouped according to treatment assigned at randomization). Participants analyzed in this outcome measure were those included in MMRM analysis.

ArmMeasureValue (MEAN)Dispersion
Sham ComparatorChange From Baseline in Number of Absolute Scotomatous Points Assessed by Mesopic Microperimetry at Week 485.4 number of absolute scotomatous pointsStandard Error 1.6
Lampalizumab Q4WChange From Baseline in Number of Absolute Scotomatous Points Assessed by Mesopic Microperimetry at Week 485.0 number of absolute scotomatous pointsStandard Error 1.5
Lampalizumab Q6WChange From Baseline in Number of Absolute Scotomatous Points Assessed by Mesopic Microperimetry at Week 486.7 number of absolute scotomatous pointsStandard Error 1.5
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline number of absolute scotomatous points, GA lesion location, contiguity, biomarker status, modified baseline BCVA and sex.p-value: 0.8495% CI: [-4.8, 3.9]MMRM
Comparison: Week 48: MMRM analysis uses change as response variable and included treatment group, visit, treatment-by-visit interaction, baseline number of absolute scotomatous points, GA lesion location, contiguity, biomarker status, modified baseline BCVA and sex.p-value: 0.558795% CI: [-3.1, 5.7]MMRM
Secondary

Percentage of Participants With Less Than 15 Letters Loss From Baseline in BCVA Score at Week 48

Loss of less than 15 letters from baseline was assessed by the ETDRS chart at a starting distance of 4 meters (m). Data were collected up to Week 48 instead of Week 96, due to early termination of the study.

Time frame: Week 48

Population: ITT population included all the participants who were randomized to the study. Reported here is the number of participants for whom data were collected.

ArmMeasureValue (NUMBER)
Sham ComparatorPercentage of Participants With Less Than 15 Letters Loss From Baseline in BCVA Score at Week 4887.1 percentage of participants
Lampalizumab Q4WPercentage of Participants With Less Than 15 Letters Loss From Baseline in BCVA Score at Week 4888.2 percentage of participants
Lampalizumab Q6WPercentage of Participants With Less Than 15 Letters Loss From Baseline in BCVA Score at Week 4886.8 percentage of participants
p-value: 0.689295% CI: [0.7, 1.8]Regression, Logistic
p-value: 0.910495% CI: [0.6, 1.6]Regression, Logistic
Secondary

Percentage of Participants With Less Than 15 Letters Loss From Baseline in LLVA Score at Week 48

Loss of less than 15 letters from baseline was assessed by the ETDRS chart at a starting distance of 4 m. Data were collected up to Week 48 instead of Week 96, due to early termination of the study.

Time frame: Week 48

Population: ITT population included all the participants who were randomized to the study. Reported here is the number of participants for whom data were collected.

ArmMeasureValue (NUMBER)
Sham ComparatorPercentage of Participants With Less Than 15 Letters Loss From Baseline in LLVA Score at Week 4890.1 percentage of participants
Lampalizumab Q4WPercentage of Participants With Less Than 15 Letters Loss From Baseline in LLVA Score at Week 4892.1 percentage of participants
Lampalizumab Q6WPercentage of Participants With Less Than 15 Letters Loss From Baseline in LLVA Score at Week 4889.6 percentage of participants
p-value: 0.370795% CI: [0.7, 2.2]Regression, Logistic
p-value: 0.838295% CI: [0.6, 1.6]Regression, Logistic

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026